Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klas Bergenheim

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cost Effectiveness and Resource Allocation : C/E|August 6, 2015
Validation of the UKPDS 82 risk equations within the Cardiff Diabetes ModelPhilip McEwan, Thomas Ward, Hayley Bennett, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 5, 2014
Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UKHayley Bennett, Phil McEwan, Klas Bergenheim, et al.
Clinical Drug Investigation|February 2, 2012
Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysisWilma Erhardt, Klas Bergenheim, Isabelle Duprat-Lomon, et al.
Current Medical Research and Opinion|January 6, 2006
Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)Phil McEwan, John R Peters, Klas Bergenheim, et al.
Plos One|September 16, 2016
The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes MellitusPhil McEwan, Hayley Bennett, Jonathan Fellows, et al.
Primary Care Diabetes|October 18, 2011
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in SwedenOla Granström, Klas Bergenheim, Phil McEwan, et al.
Diabetes, Obesity & Metabolism|February 11, 2020
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United KingdomHayley Bennett, Amarjeet Tank, Marc Evans, et al.
Primary Care Diabetes|May 21, 2014
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countriesUgne Sabale, Mattias Ekman, Ola Granström, et al.
Pharmacoeconomics|January 22, 2016
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes MellitusMartin Henriksson, Ramandeep Jindal, Catarina Sternhufvud, et al.
Pharmacoeconomics|June 8, 2010
Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes carePhil McEwan, Klas Bergenheim, Yong Yuan, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cost Effectiveness and Resource Allocation : C/E|August 6, 2015
Validation of the UKPDS 82 risk equations within the Cardiff Diabetes ModelPhilip McEwan, Thomas Ward, Hayley Bennett, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 5, 2014
Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UKHayley Bennett, Phil McEwan, Klas Bergenheim, et al.
Clinical Drug Investigation|February 2, 2012
Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysisWilma Erhardt, Klas Bergenheim, Isabelle Duprat-Lomon, et al.
Current Medical Research and Opinion|January 6, 2006
Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)Phil McEwan, John R Peters, Klas Bergenheim, et al.
Plos One|September 16, 2016
The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes MellitusPhil McEwan, Hayley Bennett, Jonathan Fellows, et al.
Primary Care Diabetes|October 18, 2011
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in SwedenOla Granström, Klas Bergenheim, Phil McEwan, et al.
Diabetes, Obesity & Metabolism|February 11, 2020
Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United KingdomHayley Bennett, Amarjeet Tank, Marc Evans, et al.
Primary Care Diabetes|May 21, 2014
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countriesUgne Sabale, Mattias Ekman, Ola Granström, et al.
Pharmacoeconomics|January 22, 2016
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes MellitusMartin Henriksson, Ramandeep Jindal, Catarina Sternhufvud, et al.
Pharmacoeconomics|June 8, 2010
Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes carePhil McEwan, Klas Bergenheim, Yong Yuan, et al.
Pageof 3